[Form 4] MIRA Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Erez Aminov, Chief Executive Officer and Director of MIRA Pharmaceuticals, Inc. (MIRA), reported on Form 4 that 62,500 restricted stock units (RSUs) vested and were issued to him on 08/29/2025 at a reported price of $1.37 per share. The RSUs were granted under the company's 2022 Omnibus Incentive Plan and vesting followed achievement of specified milestones under the Reporting Person's Executive Incentive Compensation Plan.

Following the issuance, Aminov beneficially owned 844,700 shares according to the filing. The Form 4 was signed on 09/03/2025.

Positive

• 62,500 RSUs vested and were issued to the CEO on 08/29/2025, reflecting a completed milestone-based compensation event
• Post-transaction beneficial ownership of 844,700 shares reported, providing transparency on insider holdings
• Grant source disclosed: RSUs issued from the 2022 Omnibus Incentive Plan and tied to the Executive Incentive Compensation Plan

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO received 62,500 RSUs vesting immediately, increasing reported beneficial ownership to 844,700 shares.

The filing documents a non-cash compensation event: 62,500 RSUs granted under the 2022 Omnibus Incentive Plan vested on 08/29/2025 due to milestone achievement under the Executive Incentive Compensation Plan. The reported price column shows $1.37, and the post-transaction beneficial ownership is 844,700 shares. This disclosure is a routine insider filing and does not include additional financial metrics or dilution details.

Corporate Governance Expert

TL;DR: Immediate vesting of milestone-based RSUs reported by the CEO; filing confirms grant source and post-transaction ownership.

The Form 4 states the RSUs were issued from the 2022 Omnibus Incentive Plan as a result of achieving specified milestones under the executive plan. The report clarifies the relationship of the reporting person to the issuer as both CEO and director. The disclosure appears complete for this transaction and meets Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aminov Erez

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	08/29/2025		A		62,500	A	$1.37	844,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 62,500 RSUs vesting immediately, granted and issued to the Reporting Person from the Issuer's 2022 Omnibus Incentive Plan in connection with the Reporting Person's achievement of certain milestones pursuant to the Reporting Person's Executive Incentive Compensation Plan.

	/s/ Erez Aminov	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MIRA (MIRA) report on Form 4?

The Form 4 reports that CEO and Director Erez Aminov had 62,500 RSUs vest and be issued on 08/29/2025.

How many shares does Erez Aminov beneficially own after the transaction?

Following the reported issuance, the Form 4 shows Aminov beneficially owned 844,700 shares.

Under what plan were the RSUs granted to the reporting person?

The RSUs were granted and issued under the company’s 2022 Omnibus Incentive Plan and vested due to milestones under the Executive Incentive Compensation Plan.

What date did the RSUs vest and what price is listed in the filing?

The transaction date is 08/29/2025 and the filing lists a price of $1.37 in the transaction table.

When was the Form 4 signed and filed?

The Form 4 bears the reporting person’s signature dated 09/03/2025.